A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C

A. Mangia, N. Minerva, M. Annese, G. Leandro, M. R. Villani, R. Santoro, V. Carretta, D. Bacca, A. Giangaspero, M. Bisceglia, F. Ventrella, G. Dell'Erba, A. Andriulli

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to compare, in an open-label study, the efficacy and safety of a combination of interferon (IFN) and amantadine (AMA) with that of IFN alone in previously untreated patients with chronic hepatitis C. A total of 200 patients were randomized to 6 MU of IFN-α2a 3 times per week, with 200 mg of AMA daily (n = 99) or to an identical dose of interferon α2a (n = 101). Patients were treated for 12 months and observed for 6 months' posttreatment. At the completion of treatment, 28.7% of patients in the monotherapy group and 45.5% in the combination group had a virologic response (P = .014). At 6 months' posttreatment, a sustained virologic response was observed in 16.8% (95% CI: 9-23) of patients with IFN alone versus 29.3% (95% CI: 19-37) of patients who were treated with combination therapy (P = .036). In each of the 2 treatments, genotype was the only predictive parameter for a sustained response: At the logistic regression analysis, therapy and genotype were the only 2 parameters with an independent predictive value. In the combination group, at examination of month 3, hepatitis C virus (HCV)-RNA status had a 97.6% (95% CI: 93-102) positive predictive value and a 50% (95% CI: 37-63) negative predictive value for a sustained virologic clearance. A substantial proportion of naïve patients with chronic hepatitis C have an end-of-treatment and end-of-follow-up virologic and biochemical response to a combination of IFN and AMA. This new treatment appears safe and well tolerated.

Original languageEnglish
Pages (from-to)989-993
Number of pages5
JournalHepatology
Volume33
Issue number4
DOIs
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C'. Together they form a unique fingerprint.

Cite this